ASC30美国IIa期完成患者入组，将于Q4读出数据

Group 1: Clinical Trial Progress - ASC30's Phase IIa trial in the US has completed patient enrollment, with data expected in Q4 2025[2] - The trial involves 125 participants, all of whom are either obese (BMI ≥ 30 kg/m²) or overweight with at least one weight-related comorbidity (27 kg/m² ≤ BMI < 30 kg/m²)[2] - The primary endpoint is the percentage change in average weight from baseline at week 13[2] Group 2: Product Efficacy and Market Position - ASC30 demonstrated a 6.5% average weight reduction relative to baseline over a 4-week treatment period in the Phase Ib trial[3] - ASC30 is the first and only small molecule GLP-1 receptor agonist that can be administered both as a monthly injection and a daily oral tablet for obesity treatment[3] - The company holds global compound patent protection until 2044, enhancing its competitive edge in the obesity treatment market[3] Group 3: Future Prospects and Recommendations - The company is positioned as an innovative biotech firm with a strong pipeline, including ASC30 and ASC47 for obesity treatment[4] - ASC40's Phase III trial data is expected in June 2025, showing significant efficacy compared to existing therapies[4] - The company has sufficient cash reserves to support multiple ongoing research projects, indicating a robust financial position[4]